novo nordisk eli lilly - Search News

News

Novo Nordisk to sell weight-loss drug for $499

Reuters on MSN · 21m

Novo Nordisk offers Ozempic at $499 per month to eligible US cash-paying customers

Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients with type 2 diabetes in the U.S. via its own pharmacy, a tie-up with telehealth service GoodRx and other platforms.

Fox Business on MSN · 1h

Novo Nordisk to sell weight-loss drug for $499 to eligible customers

Cash-paying type 2 diabetes patients in the United States can now access Novo Nordisk's Ozempic for $499 per month through multiple pharmacy platforms.

Seeking Alpha · 55m

Novo Nordisk's Loss Is Eli Lilly's Gain, And Vice Versa

Novo Nordisk A/S gains momentum with FDA approval for Wegovy and strategic pricing. Click for why Novo outshines Eli Lilly and Company (LLY) for long-term growth.

3d

Novo Nordisk's Lead Fades, Eli Lilly Holds Course For Outsized Gains, Says Analyst

On Thursday, Eli Lilly and Co. (NYSE:LLY) said it will sharply increase the list price of its weight-loss and type 2 diabetes ...

2d

Eli Lilly Vs. Novo Nordisk: Correction Overly Done - GLP-1 Market Leadership/ Robust Pipelines Ahead

Novo Nordisk's (NVO) corrections amid AI market rotation might be an opportunity, due to GLP-1 market leadership & balanced ...

4h

Novo Nordisk stock soar 5% today: here’s why analysts are bullish

Novo Nordisk stock gains as FDA expands Wegovy use, while Ozempic price cut aims to boost access and defend market share.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results